Previous 10 | Next 10 |
2023-11-02 00:00:34 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q3 2023 Earnings Call Nov 01, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Tr...
2023-11-01 20:33:02 ET Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Conference Call November 01, 2023, 04:30 PM ET Company Participants Francesca Nolan - IR Director Douglas Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer an...
2023-11-01 16:13:37 ET More on Sarepta Therapeutics Sarepta Stock Tanks As DMD Gene Therapy Fails Confirmatory Study, Risks Market Withdrawal Sarepta's Elevidys: Secondary Outcomes Hold Regulatory Promise Capricor Therapeutics, Sarepta Therapeutics: A Promising Clini...
ELEVIDYS net product revenues for the quarter totaled $69.1 million Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2023 totaled $331.8 million Net product revenues for the third quarter 2023 totaled $309.3 million, a...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Sarepta Therapeutics Inc. (SRPT) is expected to report $-1.63 for Q3 2023
2023-10-31 17:36:24 ET More on Sarepta Therapeutics Sarepta in selloff after late-stage setback for Duchenne candidate Sarepta's Elevidys: Secondary Outcomes Hold Regulatory Promise Capricor Therapeutics, Sarepta: Promising Clinical-Stage Biotech And Commercial-Stage...
2023-10-31 14:28:31 ET Summary Sarepta Therapeutics' stock plummets after its gene therapy drug ELEVIDYS fails to meet its primary endpoint in a confirmatory study. SRPT had previously secured accelerated approval for ELEVIDYS to treat Duchenne Muscular Dystrophy from the FDA. ...
2023-10-31 12:47:58 ET Summary EMBARK study mixed results: Elevidys missed primary endpoint but showed strong secondary outcomes, affecting FDA approval calculus for DMD. Strong financials: Q2 revenue growth and a 33.6-month cash runway diminish near-term financing risk; operation...
2023-10-31 11:52:06 ET Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark study evaluating Elevidys in treating young patients with Duchen...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...